Ken Ren

Phase II Multicenter, Open-Label Study of Oral ENMD-2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.

C. Brennan, O. Basturk, P. Kingham, 2020, The oncologist.

Abstract 1642: Evaluation of ENMD-2076 in combination with anti-PD1 in syngeneic cancer models

M. Bray, R. Kiarash, G. Fletcher, 2017 .